Affiliation: Elan Pharmaceuticals
- Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA)Irina Mikolaenko
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 2196, USA
J Neuropathol Exp Neurol 64:156-62. 2005..Finally, the coexistence of Abeta amyloid and alpha-synuclein pathology in AD brains suggests that the pathogenic mechanism/s leading to the accumulation of Abeta and alpha-synuclein may be similar...
- A quarter century of advancing treatment for Alzheimer's disease with Leon J. ThalMichael Grundman
Alzheimer s Disease Clinical Development Program, Elan Pharmaceuticals, Inc, San Francisco, CA, USA
Alzheimers Dement 4:S51-5. 2008
- Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?Michael Grundman
Elan Pharmaceuticals, Inc, San Diego, CA
Alzheimers Dement 2:220-33. 2006..This article summarizes the presentations and discussions of that meeting...
- The oldest old and the 90+ StudyClaudia H Kawas
Department of Neurology, Department of Neurobiology and Behavior, University of California at Irvine, Irvine, CA, USA
Alzheimers Dement 4:S56-9. 2008..Through our collective efforts, we will continue the scientific work that Leon so strongly supported...
- Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementiaArchana B Balasubramanian
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA
Neurology 79:915-21. 2012..The purpose of this study was to compare longitudinal cognitive performance in oldest-old individuals without dementia with and without AD neuropathology...
- Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairmentMichael Grundman
Department of Neurosciences, University of California, San Diego, La Jolla 92093 0949, USA
J Mol Neurosci 20:241-8. 2003..We conclude that the relationship between hippocampal volume and risk of AD is likely tied to reduced memory performance and not associated with impairment in nonmemory cognitive domains...
- Disability in the oldest-old: incidence and risk factors in the 90+ studyDaniel J Berlau
Department of Neurology, University of California Irvine, CA 92697, USA
Am J Geriatr Psychiatry 20:159-68. 2012..To measure the incidence of disability in individuals aged 90 years and older and examine factors that may increase risk of disability...
- Cognitive impairment in nondemented oldest-old: prevalence and relationship to cardiovascular risk factorsCarrie B Peltz
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA
Alzheimers Dement 8:87-94. 2012..To determine the prevalence and types of cognitive impairment in a sample of nondemented participants aged ≥90 (the oldest-old) and to examine the relationships between cognitive impairment and cardiovascular risk factors...
- Dementia incidence continues to increase with age in the oldest old: the 90+ studyMaria M Corrada
Department of Neurology, University of California, Irvine, CA 92697 1400, USA
Ann Neurol 67:114-21. 2010..Here, we estimate age- and sex-specific incidence rates of all-cause dementia in people aged 90 years and older, including estimates for centenarians...
- Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-oldB Adar Kravitz
Department of Neurobiology and Behavior, University of California at Irvine, Irvine, CA, USA
Alzheimers Dement 5:318-23. 2009..Using a cross-sectional design, we examined whether high levels of serum CRP are associated with increased odds of prevalent dementia in the oldest-old...
- Synaptic proteins, neuropathology and cognitive status in the oldest-oldElizabeth Head
Institute of Brain Aging and Dementia, University of California, Irvine, CA 92697 4540, USA
Neurobiol Aging 30:1125-34. 2009..Frontal cortex SYN protein levels may protect neuronal function in oldest-old individuals and reflect compensatory responses that may be involved with maintaining cognition...
- Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2Sudha Seshadri
Department of Neurology, Boston University School of Medicine, MA, USA
Alzheimers Dement 7:35-52. 2011..Improved accuracy in the clinical diagnosis of AD is anticipated with the addition of molecular and structural biomarkers in the next generation of epidemiological studies...
- Apolipoprotein E genotype, dementia, and mortality in the oldest old: the 90+ StudyMaria M Corrada
Department of Neurology, University of California Irvine, CA, USA
Alzheimers Dement 9:12-8. 2013....
- Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairmentsCarrie B Peltz
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA
Neurology 77:1906-12. 2011..To examine the incidence of dementia among the oldest-old people with normal cognition and different types of cognitive impairment...
- A population-based clinicopathological study in the oldest-old: the 90+ studyMaria M Corrada
Department of Neurology, University of California, Irvine, Irvine, CA 92697 1400, USA
Curr Alzheimer Res 9:709-17. 2012....
- APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest oldDaniel J Berlau
Institute of Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 1400, USA
Neurology 72:829-34. 2009..This would predict, even with advanced age, that APOE2 carriers would be less likely to have dementia and less likely to meet pathologic criteria for AD...
- High levels of serum C-reactive protein are associated with greater risk of all-cause mortality, but not dementia, in the oldest-old: results from The 90+ StudyB Adar Kravitz
Department of Neurobiology and Behavior, University of California at Irvine, Irvine, California, USA
J Am Geriatr Soc 57:641-6. 2009..To evaluate whether high levels of C-reactive protein (CRP) in serum are associated with greater risk of all-cause dementia or mortality in the oldest-old...
- Alzheimer's and dementia in the oldest-old: a century of challengesClaudia H Kawas
Department of Neurology, University of California, Irvine, CA 92697 4540, USA
Curr Alzheimer Res 3:411-9. 2006....
- Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trialPaul S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
JAMA 289:2819-26. 2003....
- Poor physical performance and dementia in the oldest old: the 90+ studySzofia S Bullain
Department of Neurology, University of California, Irvine, CA 92967, USA
JAMA Neurol 70:107-13. 2013..To examine the cross-sectional relationship between physical performance and dementia in the oldest old (those ≥ 90 years of age)...
- Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ StudyClaudia H Kawas
Department of Neurology, University of California, Irvine, Irvine, CA, USA
Alzheimers Dement 9:199-203. 2013..The goal of this study was to examine cross-sectional and longitudinal associations between cognitive performance and beta amyloid (Aβ) load determined by florbetapir F18 positron emission tomography (PET) in nondemented oldest-old...
- Abnormal EEGs in cognitively and physically healthy oldest old: findings from the 90+ studyCarrie Brumback Peltz
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, California 92697 1400, USA
J Clin Neurophysiol 27:292-5. 2010..The high rates of EEG abnormalities found in these physically and cognitively healthy participants prompt reappraisal of pathologic significance in this unique population...
- Non-alcoholic beverage and caffeine consumption and mortality: the Leisure World Cohort StudyAnnlia Paganini-Hill
Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, CA, USA
Prev Med 44:305-10. 2007..To examine the effects of non-alcoholic beverage and caffeine consumption on all-cause mortality in older adults...
- Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use CriteriaMichael Grundman
Global R and amp D Partners, LLC, San Diego, Calif, USA
Dement Geriatr Cogn Disord 41:80-92. 2016..This study compared the impact of amyloid PET on diagnosis and management in subjects likely to either meet or not meet AUC...
- The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseGuy M McKhann
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Alzheimers Dement 7:263-9. 2011..Much work lies ahead for validating the biomarker diagnosis of AD dementia...
- Diagnosing dementia in the oldest-oldCarrie Brumback-Peltz
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697 4540, United States
Maturitas 70:164-8. 2011..More research is necessary in the oldest-old to better understand the etiologies of dementia in this age group, and factors that may affect the expression of disease as we age...
- Estrogen levels do not correlate with improvement in cognitionLeon J Thal
Department of Neurosciences, University of California, San Diego, School of Medicine, 9500 Gilman Dr, La Jolla, CA 92093, USA
Arch Neurol 60:209-12. 2003..To investigate whether an association exists between estradiol and estrone levels and measures of cognitive functioning in women with Alzheimer disease (AD) treated with conjugated equine estrogen (Premarin; Wyeth-Ayerst, Philadelphia, Pa)...
- Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trialsJesse M Cedarbaum
Cytokinetics, Inc, South San Francisco, CA, USA
Alzheimers Dement 9:S45-55. 2013....
- Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patientsMing Ji
Division of Epidemiology and Bisotatistics, Graduate School of Public Health, San Diego State University, 5500 Campanile Drive, San Diego, CA 92182 4162, USA
J Alzheimers Dis 5:375-82. 2003..Our finding supports the clinical belief of the existence of a change point during cognitive decline among AD patients and suggests the use of change point models for the longitudinal modeling of cognitive decline in AD research...
- Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive declineMichael Grundman
Department of Neurosciences, University of California, San Diego, CA, USA
Alzheimer Dis Assoc Disord 27:4-15. 2013..8% (95% CI, 25.0%-41.6%). In summary, amyloid imaging results altered physician's diagnostic thinking, intended testing, and management of patients undergoing evaluation for cognitive decline...
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable WorkgroupReisa A Sperling
Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
Alzheimers Dement 7:367-85. 2011..The workgroup proposes recommendations for the detection and monitoring of ARIA in ongoing AD clinical trials, as well as directions for future research...
- A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's diseaseDale B Schenk
Elan Pharmaceuticals, San Francisco, CA 94080, USA
Neurodegener Dis 2:255-60. 2005..These findings have led to newer alternative A beta immunotherapy approaches that include both active and passive approaches that are currently in clinical testing in both the USA and Europe...
- Sensitivity and specificity of the mini-mental state examination for identifying dementia in the oldest-old: the 90+ studyKristin Kahle-Wrobleski
Institute of Brain Aging and Dementia, University of California at Irvine, Irvine, California 92697, USA
J Am Geriatr Soc 55:284-9. 2007..To evaluate the sensitivity and specificity of the Mini-Mental State Examination (MMSE) in identifying dementia in the oldest-old when stratified by age and education...
- Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairmentRuth A Mulnard
Departments of Neurology, and Neurobiology and Behavior, University of California Irvine, Gillespie NRF, Room 1113, Irvine, CA 92697 4540, USA
Curr Neurol Neurosci Rep 4:368-73. 2004..Additional basic and clinical investigations are necessary to examine different forms and dosages of estrogens, other populations, and the relevance of timing and duration of exposure...
- Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trialMichael Grundman
Department of Neurosciences, University of California, San Diego, La Jolla, USA
J Mol Neurosci 19:23-7. 2002..In summary, these data suggest that MRI hippocampal volume may be a useful correlate of disease severity in MCI subjects and a prognostic indicator of subsequent AD...
- DRD4 genotype predicts longevity in mouse and humanDeborah L Grady
Department of Biological Chemistry, College of Medicine, University of California, Irvine, California 92697, USA
J Neurosci 33:286-91. 2013..These results support the hypothesis that DRD4 gene variants contribute to longevity in humans and in mice, and suggest that this effect is mediated by shaping behavioral responses to the environment...
- Medications and diet: protective factors for AD?Claudia H Kawas
Department of Neurology, Institute for Brain Aging and Dementia, University of California Irvine, 1121 Gillespie, Irvine, CA 92627 4540, USA
Alzheimer Dis Assoc Disord 20:S89-96. 2006..At present, there is insufficient evidence to make public health recommendations, but these studies can provide potentially important clues and new avenues for clinical and laboratory research...
- Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errorsKyle B Womack
Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9129, USA
Arch Neurol 68:329-37. 2011....
- Association of body mass index and weight change with all-cause mortality in the elderlyMaria M Corrada
Department of Neurology, School of Medicine, University of California, Irvine, 92697 1400, USA
Am J Epidemiol 163:938-49. 2006..This study highlights the influence on older-age mortality risk of being overweight or obese in young adulthood and underweight or obese in later life...
- Neuronal localization of C1q in preclinical Alzheimer's diseaseMaria I Fonseca
Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA
Neurobiol Dis 15:40-6. 2004..Thus, it is possible that this neuronal-associated C1q reflects an early, but transient, response to injury that may modulate the progression of neurological dysfunction in AD...
- Clinical practice. Early Alzheimer's diseaseClaudia H Kawas
Institute for Brain Aging and Dementia and the Departments of Neurology and Neurobiology and Behavior, University of California, Irvine, CA 92697 4540, USA
N Engl J Med 349:1056-63. 2003
- Diet and the risk for Alzheimer's diseaseClaudia H Kawas
Ann Neurol 59:877-9. 2006
- Hippocampal neurons in pre-clinical Alzheimer's diseaseMark J West
Department of Neurobiology, Institute of Anatomy, Building 234, University Park, Aarhus 8000, Denmark
Neurobiol Aging 25:1205-12. 2004..However, we did not observe a significant loss of neurons in CA1 or any of the other subdivisions of the hippocampus in preclinical AD...
- Survival following dementia onset: Alzheimer's disease and vascular dementiaAnnette L Fitzpatrick
Department of Epidemiology, University of Washington, Seattle, WA 98115, USA
J Neurol Sci 229:43-9. 2005..4 years for mixed dementia, and 11.0 years for matched controls with normal cognition. While persons with VaD died primarily from cerebrovascular disease, those with AD/mixed dementia died more frequently from dementia/failure to thrive...
- Immune reactive cells in senile plaques and cognitive decline in Alzheimer's diseaseAnne K Vehmas
Department of Pathology, Neuropathology Division, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 558, Baltimore, MD 21205 2196, USA
Neurobiol Aging 24:321-31. 2003..Tau immunoreactivity appears as the strongest morphological correlate of dementia...
- Depressive symptoms, sex, and risk for Alzheimer's diseaseGloria Dal Forno
Clinical Neurosciences, University Campus BioMedico and Associazione Fatebenefratelli per la Ricerca A Fa R, Via dei Compositori 130 132, 00128 Rome, Italy
Ann Neurol 57:381-7. 2005..We conclude that the impact of depressive symptoms on risk for dementia and AD may vary with sex. Further studies assessing separately the role of depression as a risk factor in men and women are necessary...
- Informed consent for Alzheimer's disease clinical trials: a survey of clinical investigatorsJason H T Karlawish
Internal Ethics Committee of the Alzheimer s Disease Cooperative Study
IRB 24:1-5. 2002